FibroBiologics (FBLG) CSO granted 61,607 stock options at $1.38

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Khoja Hamid

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	61,607	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 61,607 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 61,607 options Exercise price: $1.38 per share Post-grant option holdings: 61,607 options +3 more

6 metrics

Options granted 61,607 options Stock Option (Right to Buy) grant on May 4, 2026

Exercise price $1.38 per share Conversion or exercise price for common stock underlying options

Post-grant option holdings 61,607 options Total derivative securities following the grant, held directly

Expiration date May 4, 2036 Option expiration for the granted stock options

Initial vesting 25% after 1 year One fourth of option shares vest on first anniversary of grant date

Remaining vesting period 36 monthly installments Balance vests monthly after first year, contingent on continuous service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.3800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"option shares shall vest on the one-year anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"until fully vested so long as the reporting person remains in continuous service"

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khoja Hamid

(Last)

(First)

(Middle)

C/O FIBROBIOLOGICS, INC.

9350 KIRBY DRIVE., SUITE 300

(Street)

HOUSTON

TEXAS

77054

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.38	05/04/2026		A		61,607		⁽¹⁾	05/04/2036	Common Stock	61,607	$0	61,607	D

Explanation of Responses:

1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods

	/s/ Hamid Khoja	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did FibroBiologics (FBLG) report for Hamid Khoja?

FibroBiologics reported that Chief Scientific Officer Hamid Khoja received a stock option grant for 61,607 shares. These options allow him to buy common stock at a fixed price in the future, subject to vesting based on continued service with the company.

How many FibroBiologics (FBLG) options were granted to the Chief Scientific Officer?

The Chief Scientific Officer received options for 61,607 shares of FibroBiologics common stock. This entire amount is reflected as holdings following the transaction, indicating the grant created a new option position for the executive in this filing.

What is the exercise price of Hamid Khoja’s FibroBiologics (FBLG) stock options?

The granted stock options have an exercise price of $1.38 per share. This means Khoja can buy FibroBiologics common stock at $1.38 once the options vest, regardless of the market price at that time.

How do the FibroBiologics (FBLG) options granted to Hamid Khoja vest over time?

One quarter of the 61,607 option shares vest on the one-year anniversary of the May 4, 2026 grant date. The remaining options then vest in 36 equal monthly installments, conditioned on Khoja remaining in continuous service with FibroBiologics.

When do Hamid Khoja’s FibroBiologics (FBLG) stock options expire?

The stock options granted to Hamid Khoja are scheduled to expire on May 4, 2036. If not exercised by that date, any unexercised vested options will lapse and no longer allow the purchase of FibroBiologics common stock.

Is Hamid Khoja’s FibroBiologics (FBLG) option grant a market purchase or compensation award?

The transaction is a compensation-related award, not an open-market purchase. The Form 4 classifies it as a grant or other acquisition of derivative securities, with a zero-dollar transaction price and a specified exercise price of $1.38 per share.